复方红霉素延迟起释型缓释片的研制及其体外释放

陈海霞 陈志鹏 王启荣 刘泽坤 马全龙

复方红霉素延迟起释型缓释片的研制及其体外释放

陈海霞陈志鹏王启荣刘泽坤马全龙

Compound erythromycin sustained release preparation and its in vitro release

CHEN Hai-Xia

摘要

摘要:
以重均分子量50 000聚乳酸 (polylactic acid, PLA) 为载体, 与一定比例的红霉素 (erythromycin, EM) 和醋酸泼尼松 (prednisone acetate, PNA) 混合制备复方红霉素延迟起释型缓释片。利用紫外分光光度法检测EM和高效液相法检测PNA在体外介质中的释药量。缓释片持续释放时间约为21天, EM平均含量为99.7 mg/片, RSD为0.82%; PNA平均含量为10.03 mg/片, RSD为0.93%。缓释片从第5天开始缓慢而平稳地释放,在初期的突释现象尤为显著。在21天内EM累积释放量为86.1%, PNA累积释放量为78.3%。结果表明: 缓释片制备方法可行, 释药性能良好, 临床疗效显著。

Abstract:
Using the weight-average molecular weight 50 000 polylactic acid (PLA) as a carrier, and a certain proportion of erythromycin (EM) and prednisone acetate (PNA) to mixed prepare the compound erythromycin sustained release preparation (sustained-release tablets). Using ultraviolet spectrophotometry and high performance liquid chromatography (HPLC) to detect separately the release amount of EM and PNA in vitro medium. The sustained-release tablets release for about 21 days, the average content of EM is 99.7 mg/table, RSD = 0.82%; and the average content of PNA is 10.03 mg/table, RSD = 0.93%. Within 21 days, the cumulative releases of EM and PNA are 86.1% and 78.3%, respectively. The drug release is steady and slow after 5 days, the burst release phenomenon in early stage is more significant. The results showed that the sustained-release tablet preparation method is feasible, the release performance is good and the clinical efficacy is significant.

HTML全文

参考文献(0)

施引文献

资源附件(0)